A Japanese newspaper claims that the pharma giant funded flawed research that revealed extra health benefits for one of its top-selling drugs.
Advertisement
The Scientist
Most Recent
The Science of Love, Bad Pharma, Genes, Cells and Brains, and Nature Wars
$700,000 worth of gold dust has been reported missing from a Pfizer medical research lab in Missouri.
Many vaccines are on the market for various serogroups of meningococcal disease, but a solution to provide broad protection against MenB remains elusive.
Two medical professors contend that the pharmaceutical industry is really suffering from a drive to make only marginal improvements to existing drugs.
Some 85 percent of researchers involved in promoting off-label drug use do not adequately disclose financial conflicts of interest in published articles.
Whether working for a pharmaceutical giant or a biotech start-up with a unique vision, researchers who responded to this year’s Best Places to Work in Industry survey are translating society’s most pressing scientific needs into a new generation of d
Much has changed in the 10 years since our first survey of industry researchers. Large companies are now looking to small, nimble ones for services as well as innovation.
Major pharmaceutical companies have agreed to a handful of recommendations aimed at increasing the transparency of clinical trials they fund.
GlaxoSmithKline and Johnson & Johnson contribute a total of $100 million to early-stage biotech endeavors.
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
